Nerve growth factor (NGF) treatment of rat pheochromocytoma (PC12) cells induces the synthesis of the transcription factor c-Fos, which becomes highly phosphorylated relative to that produced as a result of depolarization of the cell. A peptide derived from the carboxyl terminus of c-Fos (residues 359-370, RKGSSSNEPSSD) containing putative phosphorylation sites was used to detect a NGF-stimulated Fos kinase. NGF treatment of PC12 cells resulted in a rapid activation of a protein kinase which phosphorylated both the c-Fos peptide and authentic c-Fos at its carboxyl terminus. The kinase was selectively activated by NGF and epidermal growth factor but was not induced by depolarization or other agents. The c-Fos peptide was phosphorylated at a serine corresponding to Ser', a site critically implicated in the capacity of c-Fos to exhibit transrepressive activity [Offr, R., Dwarki, V.
The protooncogene c-fos is one member of a class of immediate early genes that are rapidly and transiently induced upon treatment of rat pheochromocytoma (PC12) cells with nerve growth factor (NGF) or a number of other agents (1) . The c-fos gene product, c-Fos, is a transcriptional regulator, mediating transactivation by interacting with AP-1 sites as a heterodimer with c-Jun (2) (3) (4) (5) (6) (7) . Two amino-terminal domains are necessary for transactivation: a basic DNA-binding domain and a leucine zipper domain through which c-Fos associates with c-Jun (8) (9) (10) . In addition to its role as a transactivator, c-Fos can repress transcription from its own promoter, as well as from those of other immediate early genes (4, (11) (12) (13) . This transrepressive function of c-Fos is independent of the basic region and leucine zipper and is mediated by the carboxyl terminus of this protein (11, 12) . A c-Fos mutant lacking the carboxyl-terminal 27 amino acids (residues 355-381) cannot repress transcription (11) . v-Fos, the oncogenic viral cognate of c-Fos, contains both the leucine zipper and DNA-binding domains-and maintains the ability to transactivate over AP-1 sites. However, v-Fos differs from c-Fos due to a deletion-induced frameshift resulting in 48 unrelated amino acids at the carboxyl terminus (13, 14) . Like c-Fos mutants lacking the carboxyl terminus, the v-Fos protein does not exhibit transrepressive activity (15) . c-Fos contains potential phosphorylation sites at its carboxyl terminus that are absent in v-Fos, one of which is phosphorylated in vivo (16, 17) . Phosphorylation of c-Fos at sites in the carboxyl-terminal region is increased upon serum stimulation of rat 208F cells (16) .
NGF treatment of PC12 cells results in the stimulation of the Trk protein-tyrosine kinase (18, 19) , initiating a signal transduction cascade and the serial activation of a number of protein kinases (20) (21) (22) (23) . As a result, many proteins show increased levels of phosphorylation, including c-Fos (24) . Curran (26) . Radiolabeled ATP was synthesized by using Gamma Prep A (Promega). The c-Fos peptide, comprising residues 359-370 (RKGSSSNEPSSD), was synthesized at facilities at the Medical University of South Carolina (Charleston) and by Coast Scientific (La Jolla, CA). c-Fos and Fos AF proteins, a gift of Tom Curran (Hoffmann-La Roche), were expressed in Escherichia coli as a His6 fusion protein as described by Abate et al. (27) .
Fos Kinase Isolation. PC12 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% horse serum and 5% fetal bovine serum in an atmosphere of 10%o CO2. The cells were collected by trituration in phosphatebuffered saline containing bovine serum albumin (1 mg/ml) and glucose (1 mg/ml), resuspended at a concentration of 2 x 106 cells per ml, and treated as described for the indicated period of time. After collection by centrifugation, the cells were lysed by sonication in 20 mM Tris, pH 7.4/1 mM EGTA, pH 7.4/100 ,uM sodium orthovanadate (lysis buffer) containing 10 mM p-nitrophenyl phosphate, essentially as described by Smith et al. (28) . The cellular lysate was centrifuged at 100,000 x g and the supernatant was collected. The soluble cell lysate was applied to a Mono Q HR 5/5 column (Pharmacia) in lysis buffer and developed with a 0-0.4 M NaCI gradient. The treated cells, but not that from untreated cells (Fig. 3, lanes  b) . To verify that Fos kinase phosphorylated Fos principally at the carboxyl terminus, a deletion mutant lacking the carboxyl-terminal 80 amino acids, Fos AF, was assayed (28, 29) . The Fos AF protein was not significantly phosphorylated (Fig. 3, lanes c) . Chromatography ofthe enzyme on the Mono S ion-exchange column demonstrated coelution of kinase activity phosphorylating both the peptide substrate and c-Fos protein (Fig. 4) 
DISCUSSION
An increase in c-fos transcription is a common response in a number of cell types to a variety of stimuli. The c-fos gene product can participate in both the activation and repression of transcription. The ability of c-Fos to differentially regulate gene expression is central to its capacity to affect cell growth, differentiation, and transformation. It is not presently clear how these multiple effects of c-Fos are achieved; however, phosphorylation of Fos and other transcription factors is likely to be a prevalent mechanism through which their activities are regulated. The protein kinases responsible for these regulatory phosphorylations are important in the hormonal control of cellular phenotype.
We have identified a NGF-regulated Fos kinase in PC12 cells. Fos kinase was distinct from previously described NGF-stimulated kinases. Fos kinase was not cAMPdependent kinase, as it was not inhibited by IP20 (at concentrations up to 1 gM), a specific peptide inhibitor of this enzyme, and cAMP-dependent kinase displays different chromatographic behavior (30, 31) . Although c-Fos is phosphorylated in vitro at its carboxyl terminus by cAMPdependent kinase (31), dibutyryl cAMP treatment of PC12 cells did not result in increased Fos kinase activity toward the peptide substrate. As previously indicated, Fos kinase was eluted separately from MAPKs (ERKs) on ion-exchange chromatography and did not phosphorylate their substrates, myelin basic protein and microtubule-associated protein 2. The PSSD motif in the Fos peptide has been identified as a potential casein kinase II site due to its similarity to the casein kinase II phosphorylation site in serum response factor (SRF; ref. 32). However, Fos kinase was not inhibited by heparin up to 1 uM, indicating that Fos kinase was not casein kinase II. This is consistent with the observations of Abate et al. (31) showing that casein kinase II does not phosphorylate c-Fos in vitro. Fos kinase was distinct from protein kinase C, as it was not stimulated by phorbol ester and had no requirement for Ca2+. Similarly, the absence of a dependence upon Ca2+ also indicated that calmodulin kinases were not responsible for this activity. Antibodies to the S61I kinase family failed to precipitate Fos kinase activity (L.K.T. and G.E.L., unpub- lished work). Moreover, the activation kinetics and chromatographic behavior of Fos kinase were inconsistent with previously reported S6 kinases in PC12 cells (20) . While Fos kinase is implicated in c-Fos phosphorylation, given its rapid activation, it is also likely to phosphorylate other substrates.
The carboxyl terminus of c-Fos is essential for the transcriptional repression exhibited by this protein (18, 26) . Ofir et al. (25) provided evidence that phosphorylation of serine residues contained within the peptide employed in the present study are necessary for transrepression. Substitution of alanine residues within the GSSS sequence (residues 361-364) inhibited the transrepressive activity of c-Fos, which was restored upon introduction of negatively charged residues into this motif (25) . The phosphorylation site at the carboxyl terminus of c-Fos has been identified as Ser362 (17), corresponding to the phosphorylation site within the c-Fos peptide substrate of the NGF-activated Fos kinase described here. The requirement for the presence of this phosphorylation site for expression of transrepressive activity strongly suggests that phosphorylation of c-Fos by a kinase with the specificity of Fos kinase regulates this event. The potential functional importance of phosphorylation at this locus is demonstrated by the enhanced transforming capacity of Fos mutants lacking serine residues 362-364 (17) .
The mechanism through which c-Fos is phosphorylated at its carboxyl terminus may be both cell type-and ligandspecific. It has been suggested that cAMP-dependent protein kinase mediates the phosphorylation of Fos within this motif, based on the ability of this kinase to phosphorylate this site in vitro and the observation that c-Fos becomes phosphorylated following forskolin treatment of JEG3 cells (17, 31) . However, dibutyryl cAMP treatment of CHO cells had no effect on c-Fos phosphorylation (16). NGF does not cause an increase in cAMP levels in PC12 cells (33) , suggesting cAMPdependent kinase is unlikely to be responsible for the resulting phosphorylation of c-Fos. It is likely that multiple, alternative mechanisms exist that activate the transrepressive function of this transcription factor. The mechanism(s) through which c-Fos exerts its transrepressive activity is presently unclear. The CarG [CC(A+T-rich),GG sequence motif] elements of the serum response element (SRE) in the Fos promoter are required for transrepression. However, c-Fos does not directly interact with this DNA motif (11) . A protein complex of SRF and p62TCF binds to the SRE and is responsible for increased c-fos transcription following growth factor or serum stimulation (34) (35) (36) (37) . It is hypothesized that a protein-protein interaction between newly synthesized c-Fos and the SRF/p62TCF complex downregulates c-fos transcription. The phosphorylation of c-Fos at its carboxyl terminus by Fos kinase is thought to render it able to participate in such an interaction. Consistent with involvement of newly synthesized c-Fos protein, ongoing protein synthesis is required for the repression of c-fos transcription following growth factor stimulation (38) . Depo 
